Therefore, ANXA8 can better reflect the prognosis in patients with ovarian serous tumors, and its correlation with prognosis was even more pronounced in patients with poor differentiation, advanced FIGO stages, and TP53 mutations. The gene discussed is TP53; the disease is ovarian serous tumor.